| Dr Tyler Dexter Kirk, DO | |
|
16000 Johnston Memorial Dr, Abingdon, VA 24211-7664 | |
| (276) 258-4435 | |
| Not Available |
| Full Name | Dr Tyler Dexter Kirk |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 16000 Johnston Memorial Dr, Abingdon, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811348535 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0102205759 (Virginia) | Secondary |
| 207Q00000X | Family Medicine | 0102205759 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johnston Memorial Hospital | Abingdon, VA | Hospital |
| Smyth County Community Hospital | Marion, VA | Hospital |
| Russell County Hospital | Lebanon, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Virginia Regional Emergency Physicians Llc | 4183991227 | 79 |
News Archive
VIVUS, Inc. today announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in adults.
Increasingly, doctors are treating lung cancer based on the genetic rearrangements driving the disease. For example, cancers that are driven by changes in the genes ALK, EGFR, and ROS1 can now all be paired with drugs that target these specific changes.
In the face of increased scrutiny of ties between industry and medical school faculty, Harvard is tightening its conflict-of-interest policies, The Boston Globe reports.
Amerigroup Corporation today announced that net income for the second quarter of 2010 was $67.2 million, or $1.31 per diluted share, versus net income of $49.6 million, or $0.94 per diluted share, for the second quarter of 2009. Second quarter of 2009 results were positively impacted by a tax adjustment of $0.43 per diluted share related to litigation settled in 2008. Excluding the tax adjustment, second quarter of 2009 net income would have been $27.2 million, or $0.51 per diluted share.
› Verified 3 days ago
| Entity Name | Wellmont Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174808216 PECOS PAC ID: 8123291739 Enrollment ID: O20120627000467 |
News Archive
VIVUS, Inc. today announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in adults.
Increasingly, doctors are treating lung cancer based on the genetic rearrangements driving the disease. For example, cancers that are driven by changes in the genes ALK, EGFR, and ROS1 can now all be paired with drugs that target these specific changes.
In the face of increased scrutiny of ties between industry and medical school faculty, Harvard is tightening its conflict-of-interest policies, The Boston Globe reports.
Amerigroup Corporation today announced that net income for the second quarter of 2010 was $67.2 million, or $1.31 per diluted share, versus net income of $49.6 million, or $0.94 per diluted share, for the second quarter of 2009. Second quarter of 2009 results were positively impacted by a tax adjustment of $0.43 per diluted share related to litigation settled in 2008. Excluding the tax adjustment, second quarter of 2009 net income would have been $27.2 million, or $0.51 per diluted share.
› Verified 3 days ago
| Entity Name | Western Virginia Regional Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386183028 PECOS PAC ID: 4183991227 Enrollment ID: O20170522001368 |
News Archive
VIVUS, Inc. today announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in adults.
Increasingly, doctors are treating lung cancer based on the genetic rearrangements driving the disease. For example, cancers that are driven by changes in the genes ALK, EGFR, and ROS1 can now all be paired with drugs that target these specific changes.
In the face of increased scrutiny of ties between industry and medical school faculty, Harvard is tightening its conflict-of-interest policies, The Boston Globe reports.
Amerigroup Corporation today announced that net income for the second quarter of 2010 was $67.2 million, or $1.31 per diluted share, versus net income of $49.6 million, or $0.94 per diluted share, for the second quarter of 2009. Second quarter of 2009 results were positively impacted by a tax adjustment of $0.43 per diluted share related to litigation settled in 2008. Excluding the tax adjustment, second quarter of 2009 net income would have been $27.2 million, or $0.51 per diluted share.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tyler Dexter Kirk, DO 16000 Johnston Memorial Dr, Abingdon, VA 24211-7664 Ph: (276) 258-4435 | Dr Tyler Dexter Kirk, DO 16000 Johnston Memorial Dr, Abingdon, VA 24211-7664 Ph: (276) 258-4435 |
News Archive
VIVUS, Inc. today announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in adults.
Increasingly, doctors are treating lung cancer based on the genetic rearrangements driving the disease. For example, cancers that are driven by changes in the genes ALK, EGFR, and ROS1 can now all be paired with drugs that target these specific changes.
In the face of increased scrutiny of ties between industry and medical school faculty, Harvard is tightening its conflict-of-interest policies, The Boston Globe reports.
Amerigroup Corporation today announced that net income for the second quarter of 2010 was $67.2 million, or $1.31 per diluted share, versus net income of $49.6 million, or $0.94 per diluted share, for the second quarter of 2009. Second quarter of 2009 results were positively impacted by a tax adjustment of $0.43 per diluted share related to litigation settled in 2008. Excluding the tax adjustment, second quarter of 2009 net income would have been $27.2 million, or $0.51 per diluted share.
› Verified 3 days ago
Jacquelyn Burt, Family Medicine Medicare: Medicare Enrolled Practice Location: 24530 Falcon Place Blvd, Suite 100, Abingdon, VA 24211 Phone: 276-619-0075 Fax: 276-619-0077 | |
Lura S Miller, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 613 Campus Dr, Suite 200, Abingdon, VA 24210 Phone: 276-628-1186 Fax: 276-628-8507 | |
Kaley Kuntz, Family Medicine Medicare: Medicare Enrolled Practice Location: 613 Campus Dr Ste 200, Abingdon, VA 24210 Phone: 276-628-1186 Fax: 276-628-8507 | |
Nermene George Wilson, MD Family Medicine Medicare: Medicare Enrolled Practice Location: Primary Care Center, 613 Campus Drive Suite #200, Abingdon, VA 24210 Phone: 714-326-6001 | |
Dr. Kellie Miranda Smith Blackwell, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 117 Cook St, Abingdon, VA 24210 Phone: 276-619-5052 Fax: 276-619-5115 | |
William M Handy, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 389 Falls Nwdr, Abingdon, VA 24210 Phone: 276-623-0740 Fax: 276-623-0660 | |
Lauren Ashley Mcgee, D.O Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 16000 Johnston Memorial Dr, Abingdon, VA 24211 Phone: 276-258-4435 |